Dermata Therapeutics Warrant
DRMAW
DRMAW was delisted on the 17th of August, 2026.
3 hedge funds and large institutions have $15.5K invested in Dermata Therapeutics Warrant in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
7% more capital invested
Capital invested by funds: $14.5K → $15.5K (+$958)
0.61% more ownership
Funds ownership: 0.71% → 1.32% (+0.61%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$156 |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$7 |
Top Sellers
DRMAW Hedge Fund Activity: Q2 2026 in Review
3 institutional investors reported a position in Dermata Therapeutics Warrant (DRMAW) for Q2 2026, worth a combined $15.5K — up 6.6% from $14.5K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new DRMAW positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $156.
- 3 institutional investors held Dermata Therapeutics Warrant (DRMAW) as of Q2 2026, up from 2 in Q1 2026.
- Funds reported $15.5K of Dermata Therapeutics Warrant stock for Q2 2026, up 6.6% quarter-over-quarter.
- 1 fund opened new Dermata Therapeutics Warrant positions in Q2 2026 and 0 closed out, a net change of +1 holder.
- The largest Dermata Therapeutics Warrant buyer in Q2 2026 was Virtu Financial, an estimated $156 added.
Based on aggregated 13F filings for Q2 2026.